IMGN 388

Drug Profile

IMGN 388

Alternative Names: CNTO 365; CNTO 95-DM4; IMGN-388

Latest Information Update: 23 Sep 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Centocor
  • Developer ImmunoGen
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 22 May 2012 ImmunoGen completes enrolment in its phase I trial for Solid tumours in USA (NCT00721669)
  • 29 Nov 2011 Discontinued - Phase-I for Solid tumours in USA (IV)
  • 08 Jun 2010 Preliminary efficacy and adverse events data from a phase I trial in Solid tumours presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top